MG-262 (Z-Leu-Leu-Leu-B(OH)2): A Reversible Proteasome Inhibitor for Cell Cycle and Apoptosis Research

Executive Summary: MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a potent, reversible, and cell-permeable proteasome inhibitor with an IC₅₀ of 122 nM against chymotryptic proteasome activity at 37°C in cell-based assays (APExBIO). Its boronic acid moiety confers selectivity and reversibility, distinguishing it from irreversible inhibitors (Thorne et al., 2023). MG-262 induces cell cycle arrest and apoptosis in various models, including nasal polyp fibroblasts and osteoclast precursors. It is insoluble in water but highly soluble in DMSO (≥24.57 mg/mL) and ethanol (≥96.4 mg/mL), requiring fresh solution preparation for reproducibility. Its applications range from cancer and inflammatory disease modeling to cell signaling studies, with strong peer-reviewed evidence supporting its utility.

Biological Rationale

The ubiquitin-proteasome system regulates intracellular protein degradation, modulating cell cycle progression, apoptosis, and inflammatory signaling (Thorne et al., 2023). Disruption of this system is implicated in oncogenesis, neurodegeneration, and chronic inflammatory diseases. Proteasome inhibitors such as MG-262 allow researchers to dissect these regulatory networks by selectively blocking proteasomal degradation, permitting study of pathway kinetics and protein turnover. BIRC2 and BIRC3, key IAP family proteins, are regulated via ubiquitination and proteasomal degradation, linking proteasome activity to cell death and NF-κB signaling. MG-262’s specificity for chymotryptic activity provides a precise tool for mechanistic studies in cell viability, differentiation, and apoptosis (Related Review).

Mechanism of Action of MG-262 (Z-Leu-Leu-Leu-B(OH)2)

MG-262 is a synthetic boronic peptide acid that binds reversibly to the active sites of the 20S proteasome core’s chymotrypsin-like subunit via its boronic acid group. This interaction forms a covalent but reversible adduct with the proteasome’s N-terminal threonine residue, selectively inhibiting chymotryptic activity. The compound’s cell-permeable structure allows intracellular access in both adherent and suspension cells. MG-262’s inhibition is concentration-dependent (IC₅₀ = 122 nM), reversible upon compound removal, and does not irreversibly modify proteasomal subunits (Mechanistic Insights). This enables temporal control during experimental workflows. The boronic acid moiety is essential for activity and confers enhanced selectivity over non-boronic inhibitors.

Evidence & Benchmarks

• MG-262 inhibits 20S proteasome chymotryptic activity with an IC₅₀ of 122 nM at 37°C in vitro (APExBIO).
• Reduces cell viability and induces cell cycle arrest in nasal mucosa and polyp fibroblasts via p21 and p27 upregulation, and Rb phosphorylation inhibition (Thorne et al., 2023).
• Promotes apoptosis through mitochondrial membrane depolarization, caspase-3 activation, and PARP cleavage (Application Extension).
• Suppresses osteoclast differentiation in vitro in a dose-dependent manner (Mechanistic Insights).
• Reduces proteasome activity in vivo in multiple organs following intravenous administration in animal models (APExBIO).
• MG-262 enables precise temporal inhibition, with recovery of proteasome activity upon compound washout (Workflow Detail).
• Solubility in DMSO (≥24.57 mg/mL) and ethanol (≥96.4 mg/mL) allows for high-concentration stock solutions; compound is unstable in aqueous solution (APExBIO).

Applications, Limits & Misconceptions

MG-262 is widely used in proteasome inhibition assays, apoptosis research, cell cycle arrest studies, osteoclastogenesis assays, and disease signaling analyses (Related Review). Its reversible nature provides advantages for kinetic studies and time-resolved analyses. The compound is suitable for both in vitro and in vivo models, including cancer, inflammatory, and neurodegenerative disease systems. However, it is not recommended for experiments requiring irreversible inhibition, nor is it suitable for aqueous-based delivery without compatible solvents. Researchers must prevent compound degradation by preparing solutions immediately before use and storing at -20°C. MG-262 does not inhibit non-proteasomal proteases, and its specificity reduces off-target effects seen with some non-boronic inhibitors.

Common Pitfalls or Misconceptions

• Misconception: MG-262 is an irreversible inhibitor. Fact: It is reversible, allowing recovery of proteasome function upon washout (Mechanistic Insights).
• Pitfall: Use in aqueous buffers without DMSO/ethanol leads to precipitation and loss of activity.
• Pitfall: Pre-prepared solutions degrade upon storage; always prepare fresh solutions (APExBIO).
• Misconception: MG-262 is broadly cytotoxic. Fact: Cytotoxicity is dose- and cell-type dependent, requiring titration for each system.
• Limit: MG-262 does not inhibit non-proteasomal proteases, so cannot substitute for broad-spectrum protease inhibitors.

Workflow Integration & Parameters

For in vitro applications, MG-262 (SKU A8179, APExBIO) is usually dissolved in DMSO or ethanol to prepare 10–20 mM stocks, stored at -20°C, and diluted into cell culture medium immediately before use. Effective concentrations range between 50–500 nM, depending on cell type and assay endpoint. Fresh solutions ensure maximal activity. Controls should include solvent-only and vehicle-treated cells. For in vivo studies, intravenous administration is feasible, but pharmacokinetics and organ-specific distribution must be validated. Proteasome activity should be monitored using established fluorogenic or luminescent assays.

This article extends prior coverage (MG-262 Review, Mechanistic Insights, Workflow Detail) by integrating the latest peer-reviewed data on BIRC protein signaling and highlighting experimental boundaries for reproducible proteasome inhibition.

Conclusion & Outlook

MG-262 (Z-Leu-Leu-Leu-B(OH)2) remains a gold standard for reversible, cell-permeable proteasome inhibition in cell biology, apoptosis, and disease modeling research. Its selectivity, potency, and reversible mechanism enable refined experimental designs, particularly for signaling, cell cycle, and apoptosis studies. As new evidence emerges on the differential regulation of apoptosis signaling proteins and their proteasomal turnover, MG-262 will continue to inform both basic and translational research in oncology, immunology, and neurobiology. For detailed product information and ordering, refer to the MG-262 (Z-Leu-Leu-Leu-B(OH)2) product page from APExBIO.